Safety data sheet
Standardized safety protocols and material specifications for professional use.
Certificate of Analysis
Purity verified via High-Performance Liquid Chromatography (HPLC) for #myo-cagrilintide-10mg
Cagrilintide (10mg)
Research Grade >99.3% Purity
Authorized Resellers
Available through our trusted partners
123peptide.com
Netherlands · Europe
local_shipping2-3 Business Days
Depeptidenwinkel.com
Netherlands · Europe
local_shipping2-3 Business Days
Scientific Background
Cagrilintide is a long-acting synthetic analog of amylin, a pancreatic hormone co-secreted with insulin from beta cells, engineered for once-weekly subcutaneous administration.
It selectively activates central amylin receptors in the hindbrain's area postrema to enhance satiety, slow gastric emptying, suppress postprandial glucagon release, and reduce overall food intake. Acylation extends plasma half-life to approximately 160–195 hours.
Standalone phase 2 data showed ~10.8% body weight loss at 4.5 mg weekly over 26 weeks. In the CagriSema combination, REDEFINE phase 3 trials reported 20–22.7% weight reductions over 68 weeks in adults with overweight or obesity.
Intended Research Use
- Weight management and appetite regulation research
- Amylin receptor activation and satiety signaling studies
- Metabolic control and gastric emptying research
- CagriSema combination weight loss protocols
- Obesity and type 2 diabetes metabolic investigation
menu_bookScientific Publications
Lancet (2021)
Once-weekly cagrilintide for weight management in people with overweight and obesity: a phase 2 trial
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/34798060/
Lancet (2023)
Efficacy and safety of co-administered once-weekly cagrilintide with semaglutide in type 2 diabetes
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/37364590/
N Engl J Med (2025)
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
open_in_newhttps://www.nejm.org/doi/full/10.1056/NEJMoa2502081
J Med Chem (2021)
Development of Cagrilintide, a Long-Acting Amylin Analogue
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/34288673/
FOR RESEARCH USE ONLY. This product is intended for laboratory research purposes only and is not for human consumption, medical, or diagnostic use.
Possible stacks with other peptides
Synergistic combinations for enhanced research outcomes
Cagrilintide can be stacked with GLP-1 agonists and metabolic peptides for enhanced weight management and metabolic research outcomes.
Semaglutide 10mg (10mg vial)
arrow_forwardmyo-semaglutide-10mg
Dual GLP-1 and amylin synergy (CagriSema) — the most studied combination for weight loss.
Retatrutide (10mg vial)
arrow_forwardmyo-retatrutide-10mg
Triple receptor (GLP-1/GIP/Glucagon) activation with amylin for enhanced metabolic effects.
Tesamorelin (10mg vial)
arrow_forwardmyo-tesamorelin-10mg
GH release for lean mass preservation during weight loss protocols.
5-Amino-1MQ (50mg vial)
arrow_forwardmyo-5-amino-1mq-50mg
NNMT inhibition for NAD+ and fat metabolism support.
BPC-157 (5mg vial)
arrow_forwardmyo-bpc-157-5mg
Gut health and recovery support during metabolic protocols.
Cagrilintide 5mg (5mg vial)
arrow_forwardmyo-cagrilintide-5mg
Lower-dose Cagrilintide for initial satiety and amylin pathway research — the standard titration starting point before advancing to the 10mg maintenance dose.
